Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Acquisitions (2017 - 2024)

Avalo Therapeutics (AVTX) has disclosed Acquisitions for 3 consecutive years, with $356000.0 as the latest value for Q1 2024.

  • For the quarter ending Q1 2024, Acquisitions changed N/A year-over-year to $356000.0, compared with a TTM value of $356000.0 through Dec 2024, changed N/A, and an annual FY2024 reading of $356000.0, changed N/A over the prior year.
  • Acquisitions was $356000.0 for Q1 2024 at Avalo Therapeutics, up from $1.0 in the prior quarter.
  • Across five years, Acquisitions topped out at $356000.0 in Q1 2024 and bottomed at $356000.0 in Q1 2024.